Cholesterol-linked drug enhances gene-targeting effectiveness in early research

Early findings indicate that a cholesterol-linked drug can boost the potency of gene-targeting therapies, specifically nucleic acid therapeutics like antisense oligonucleotides (ASOs). These therapies are emerging as promising treatments for diseases that have been difficult to address, including neurological disorders.

Originally published by gnews